Twist Bioscience Corporation and Ildong Pharmaceutical announced an agreement under which Ildong will license a suite of Twist VHH antibody libraries to use to discover and develop antibodies for applications in immuno-oncology. Under the terms of the agreement, Ildong will license a suite of Twist's VHH libraries for a period of three years and will use the libraries to conduct research and development activities. Twist will receive an upfront payment, annual maintenance fees and additional payments for success-based clinical and regulatory milestones as well as royalties on product sales.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
53.44 USD | +1.83% |
|
+10.25% | +44.98% |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+44.98% | 3.11B | |
+6.96% | 101B | |
+8.29% | 42.63B | |
-11.09% | 33.5B | |
+82.32% | 29.77B | |
-11.82% | 16.14B | |
+1.39% | 14.31B | |
-12.13% | 11.55B | |
+176.65% | 10.53B | |
+6.74% | 9.2B |
- Stock Market
- Equities
- TWST Stock
- News Twist Bioscience Corporation
- Twist Bioscience Corporation and Ildong Pharmaceutical Enter into Collaboration to Enhance Antibody Discovery for Applications in Immuno-Oncology